IoT in pharma manufacturing changes company culture

Digital transformation comes with unforeseen yet sometimes very beneficial consequences. Who would have guessed that introducing IoT (Internet of Things) to pharmaceutical manufacturing could have a broader transformational impact on a traditionally conservative company culture?

Conservative Pharma Industry

As a bit of background information, there are many reasons why the pharmaceutical industry tends to be more risk-averse than others. Here are some key considerations:

  • Long-term investment:
    Developing an innovative new drug easily takes 10 years and costs $2.6Bn upfront (according to the Pharmaceutical Research and Manufacturers of America, PhRMA) before the actual product reaches the market. Pharmaceutical development remains a high-cost, high-risk business where mistakes are punished harshly and can ruin a company.
  • Regulated industry
    Regulatory authorities, such as the Food and Drug Administration (FDA) in the United States and corresponding agencies around the world, closely inspect every aspect of the development, manufacturing, and marketing of medicinal drug products from pharma companies. If a company is found out of compliance with Good Manufacturing Practices (GMP), severe financial penalties can be imposed and drastic consequences loom – including shutting down the business altogether.
  • Human lives are at stake
    Pharmaceutical manufacturing is where the rubber hits the road: Any problems in the manufacturing process can easily affect product quality and thereby directly threaten the health and lives of patients. Every facet must be closely observed, and regulatory inspections are frequent and thorough. Therefore, changes to the manufacturing environment are done most reluctantly by companies to minimize risks.

The burden from these limitations weighs heavy on the organization and lends itself to a conservative mindset and cautious approach. Change is not always welcome as it induces risk that could jeopardize operations and outcomes.

Moving to IoT

The Internet of Things (IoT) is more than just a bunch of devises and sensors that communicate with each other and generate a constant stream of data: IoT affects not only how we (make things) work but can also affect how we think and the foundation for our decision-making.

The traditional process in pharmaceutical manufacturing produces batches of product. It requires many human process steps from preparing and calibrating machinery, running the batch, examining the quality and then cleaning and preparing the equipment again for the next batch of the same or an entirely different product. During the process, devices collect data in their own ‑often proprietary‑ data formats that may be hard to access. The data has to be collected, combined and interpreted in a time-consuming process full of interpretation barriers and prone to human error. Even worse, “over 70% of the data in manufacturing is never touched” according to the CEO of Bigfinite, an IoT provider, and certainly not timely. This comes at a cost as this example shows: An American pharma company reportedly lost $20 million worth of product when a $3,500 vacuum pump broke down.

Around 30% of the Top 20 pharma companies started introducing IoT in their pharmaceutical manufacturing (according to GEP, a supply-chain advisory firm) to enable faster and continuous data collection from several processes for real-time monitoring, integrated analytics, and more timely decision-making. The paramount goal was to meet regulatory demand, such as the FDA requirement for continued process verification.

What comes with IoT

However, IoT relies on Cloud computing to provide digital connectivity across the entire supply chain from production to market and across plants. IoT Cloud computing may come with the necessity to use third-party-run servers for data storage and calculations raising the all too familiar fears of pharma managers and employees. Often enough it is the employees who interpret regulatory guidance to narrowly and don’t dare to rock the boat by changing the current GMP (cGMP) out of inflated data security concerns and the doomy risk of falling out of compliance.

While care certainly needs to be taken when implementing the new technology and while processes need to remain compliant, the FDA has already shown flexibility and set a precedence in approving the shift from batch to continuous manufacturing for Johnson&Johnson’s HIV drug PREZISTA.

More recently, the regulatory concern no longer seems paramount. Instead, management understands that IoT opens the door to massive and much-needed cost savings, shorter cycle time, right-sizing operations, increased productivity and higher competitiveness in the highly competitive pharmaceutical market arena.

People transformation beyond digital

Interestingly, all these more technical aspects can distract from how IoT in pharmaceutical manufacturing can lead to a broader shift of mindset throughout the organization:

Sharing and compiling formerly compartmentalized data across different parts of an organizational practically breaks the well-established and well-protected silos in many organizations. Suddenly, everyone seems connected to everyone else in the company and departmental borders fall while the process becomes visible and more transparent in real-time.

The fundamental shift with IoT and Cloud computing forces management and workers to adapt to the new technology and to connect with others outside their immediate organizational silo. The newly integrated informatics can include Enterprise Resource Planning (ERP) and financial systems. Sharing the data trove happens not only within a manufacturing plant but also across 25 plants at Pfizer, for example.

The technology-induced visibility and management of the manufacturing process challenges the traditional mode of operation and encourages employees trying out something new. If managed well, this mindset shift can be used to crack the barriers and drive a favorable cultural change throughout the organization. It enables but also pushes employees to continuously improve manufacturing operations while it also translates and proliferates into all other aspects of their work.

Summary

IoT technology in pharmaceutical manufacturing not only improves the productivity and competitiveness while maintaining regulatory compliance but also challenges and steers employee mindset away from overly conservative restraint toward collaboration and continuous improvement – and thereby shifts the organizational in favorable directions.

Will technology always outpace us? – What we can do to keep up

We measure ‘progress’ by the speed of technological progress: The more inventions and the faster our technology evolves the more progress or society makes, right?
But we also feel like drowning in the flood of ever-more technology pouring over us.
This is not about surrender but of awareness and taking control again.

We measure ‘progress’ by the speed of technological progress: The more inventions and the faster our technology evolves the more progress or society makes, right?
But we also feel like drowning in the flood of ever-more technology pouring over us.

This is not about surrender but of awareness and taking control again.

In my linked article on LinkedIn, I researched some background in a quest to find meaning – and a way out:  How Virtual Distance beats the ‘Culture Lag’ of Technology

Please share your thoughts and experiences too – thanks.

Visit GACCNY’s Health Tech Insight Panel, Mar.29, NYC

The panel will cover innovations and trends in the health tech space and will feature Alex Fair, CEO of Medstartr, a leading medtech fund, accelerator and crowdfunding platform, Loren Busby, angel investor with Mid Atlantic Bio Angels, and Mette Dyhrberg, Founder of MyMee, a successful big data symptom management startup. It is an event you won’t want to miss!Wednesday, March 29, 2017 from 6:00 PM to 9:00 PM (EDT)

GACCNY’s Health Tech Insight Panel

We are excited to partner on a new collaboration with the German American Chamber of Commerce (GACC): an expert panel event focused on innovations in health-tech.GACC

The panel will cover innovations and trends in the health tech space and will feature Alex Fair, CEO of Medstartr, a leading medtech fund, accelerator and crowdfunding platform, Loren Busby, angel investor with Mid Atlantic Bio Angels, and Mette Dyhrberg, Founder of MyMee, a successful big data symptom management startup. It is an event you won’t want to miss!

Wednesday, March 29, 2017 from 6:00 PM to 9:00 PM (EDT)

REGISTER HERE!

Add to my calendar

Spark Labs (Bryant Park)
25 West 39th St.
14th Floor
New York, NY 10018


Agenda
6:00pm     Registration, Networking & Snacks
6:30pm     Panel Discussion: Life Science
7:45pm     More Networking & Snacks

About VentureOutventureout_logo700x700

VentureOut, the event organizer, is focused on enabling the world’s most promising technology organizations to launch into new markets, raise capital, and scale. Based on the philosophy that talent is evenly distributed but opportunity is not, VentureOut’s mission is to bridge that gap between the entrepreneurial talent around the world and the vast opportunities available to them in New York City & San Francisco. Through short-form strategy development and capital raising programs, VentureOut immerses the world’s most talented entrepreneurs into the US technology ecosystem, fast tracking their growth by establishing relationships with top tech influencers, investors, and new prospective clients. To date, VentureOut has supported the growth of over 500 companies (700+ entrepreneurs) from 20 different countries. VentureOut was founded by Brian Frumberg in 2012. (www.ventureoutny.com)

Join me at the 5th Annual Pharma PPM Toolbox in Basel/Switzerland, Mar. 6, 2015

Join me at the 5th Annual Pharma PPM Toolbox in Basel/Switzerland on March 5-6, 2015!

Presentation at 3pm on March 6, 2015

Come to discuss my talk about “Changing employee mindset to boost collaboration and engagement for extreme business results”

  • How to overcome innovation hurdles in large organizations
  • How to build an entrepreneurial culture within your company to respond to change quickly
  • Measuring success beyond money – behavior change for best practices and boosting ROI

Workshop at 3:30pm on March 6, 2015

And take my Intrapreneuring Workshop “Building an innovation framework to design, launch and execute business projects”
The workshop participants experience the role of an intrapreneur to bring a project to life using disruptive methods and collaboration.

  • Innovation Barriers and Assessment
  • Becoming an Intrapreneur
  • Resistance, Sponsor and Team
  • Prototyping, Pitching and Investor Insights
  • Implementation considerations

About the Conference

Pharma companies stand on a cross-road for a few years now.  They can choose to stick to their old ways that will probably slowly kill their business or successfully adapt to the reality of continuously shrinking pipelines and growing obstacles.

The 5th Annual Pharma PPM Toolbox will provide you with fresh ideas and solutions from experts who work hard to keep up with uncompromising market demands.

The Future of Pharma: Calls Moving to Consults (video)

Calls Moving to Consults is a thought leadership video in the “10 Inevitable Changes in Pharma 2015” series that was hosted by the stellar Richie Etwaru, Chief Digital Officer with Cegedim.

This video addresses the question:  How can the pharmaceutical industry reskill representatives to be knowledgeable consultants to physicians?

Today, sales expertise is not enough. The pharmaceutical representative needs to be a broker of information. Physicians now have very limited time – and dictate when they can meet with representatives, from whom they need comprehensive information that they can pass along to their increasingly educated patients.

In this video, Jo Ann Saitta, Chief Digital Officer of the CDM Group, Stephan Klaschka, Innovation and Healthcare Consultant, and moderator, Richie Etwaru, Chief Digital Officer at Cegedim, examine this shift and the challenges pharmaceutical companies may face in properly retraining their people. These challenges include: adopting a culture of learning agility; integrating silos of information; having the ability to serve up dynamic content; and training representatives to utilize technologies that will maximize their brief but demanding visits with physicians.

Use this link to watch all 10 videos in the series on YouTube directly – enjoy!

  • 10 Inevitable Changes in Pharma 2015 – Communication moving to Collaboration
    • Angela Miccoli
    • Wendy Mayer
  • 10 Inevitable Changes in Pharma 2015 – Content moving to Context
    • James Corbett
    • Craig DeLarge
  • 10 Inevitable Changes in Pharma 2015 – Care moving to Cure
    • Michael DePalma
    • John Nosta
  • 10 Inevitable Changes in Pharma 2015 – Compliance moving to Culture
    • Bill Buzzeo
    • Gus Papandrikos
  • 10 Inevitable Changes in Pharma 2015 – Supply Chains moving to Supply Constellations
    • Ray Wang
    • Aron Dutta
  • 10 Inevitable Changes in Pharma 2015 – Customization moving to Configuration
    • Tracy Maines
    • Krishna Cheriath
  • 10 Inevitable Changes in Pharma 2015 – Customer moving to Consumer
    • Paul Kandle
    • Mark Stevens
  • 10 Inevitable Changes in Pharma 2015 – Calls moving to Consults
    • Jo Ann Saitta
    • Stephan Klaschka
  • 10 Inevitable Changes in Pharma 2015 – Cloud moving to Crowd
    • Les Jordan
    • Krishnan Sridharan
  • 10 Inevitable Changes in Pharma 2015- Charity moving to Cause
    • Janet Carlson
    • Beth Bengtson

Read Intrapreneuring Case Study “Leading Innovation” by Ivey Business School!

The prestigious Ivey Business School of the Western University in Ontario, Canada, published an insightful new teaching case study on intrapreneuring and corporate innovation titled “Boehringer Ingelheim: Leading Innovation” in which the case writers, Professor J. Robert Mitchell, Ph.D., and Ramasastry Chandrasekhar, follow the footsteps of the newly appointed innovation director.

Meant to raise questions and serving as a learning opportunity for graduate students in academic program around the globe, this case study lifts the corporate curtain a bit to show how innovation through intrapreneuring really happens and decision points along the way.

Outline (by Ivey Publishing)

The newly appointed director of Innovation Management & Strategy at Boehringer Ingelheim, a German-based multinational pharmaceutical company, is finding his way forward in his firm’s new, first-of-its-kind role, which is central to the company’s growth rejuvenation strategy. His job has a threefold mandate: to build internal networks, to establish internal structures and to leverage internal ideas. His biggest challenge, however, may be transforming the organization’s DNA. The blockbuster business model that has characterized the company for decades is no longer appropriate. Instead, the firm needs to develop healthcare products available to end users over the counter. This shift in strategy requires innovative changes in distribution, delivery and customer focus. To accomplish this goal, he needs to institutionalize innovation so that it becomes sustainable. But in doing so, he must also identify the metrics for assessing progress. The case provides an opportunity for students to step into the shoes of an innovation leader, to develop an innovation roadmap for the organization in the face of uncertainty and to understand how to engage in innovation leadership at various levels of a global enterprise.

Learning Objective

This case has two key objectives. First, this case provides students an opportunity to grapple with the difficult decisions associated with innovation in an uncertain environment. Second, this case highlights that anyone has the ability to cultivate an entrepreneurial mindset and to lead innovation. The case divides the attributes of an innovation leader into five components: observing, questioning, experimenting, networking and associating. It shows the real-life experiences of a manager doing seemingly routine activities, who evolved into a leader who transformed the DNA of a global enterprise. The case also provides a template of the tasks, responsibilities and value-added changes as an individual moves progressively within an enterprise from an operations manager to a senior manager to an innovation leader. This case can be used either toward the beginning or toward the end of any course that addresses innovation and creative thinking in a large organization. At the beginning of a course, it illustrates the challenges of acting in the face of uncertainty in a large organization. At the end of a course, the case provides an opportunity for students to apply what they have learned about innovation, entrepreneurial thinking and innovation leadership.

Is Disruptive Innovation a Myth?

When we talk about disruptive innovation, we can easily agree that going from the days of dim candle light and sooty oil lamps to electric light was one of these breakthrough innovations, right?  Its icon, the lightbulb serves as our symbol for a great idea today.

Lightbulb idea (www.istockphoto.com)
(source: http://www.istockphoto.com)

Who invented the lightbulb?

When you ask around “who invented the lightbulb?” the answer “Thomas Edison” first comes to mind – and the answer is wrong!  Truth is that we can give credit closer to 20(!) inventors of the lightbulb! – How so?

Thomas Edison patented the first practical and commercially viable incandescent lightbulb in 1878 and a revised design in 1879.  In addition, he  offered the first efficient electricity supply system for households and businesses, which laid the foundation and cleared the path for mass-producing light bulbs in 1880.  His design was an evolution from previous, inferior designs and enabled by improved technology.

Edison's Lightbulb (source: www.unmuseum.org)
Edison’s Lightbulb (source: http://www.unmuseum.org)

 

Sitting in the dark without Edison?

No worries, we would not stay sitting in the dark.  It appears safe to say that even if Thomas Edison was never born, the practical incandescent lightbulb would have been developed around the same time – by someone else.

Looking back in history, Humphrey Davy invented electric light in 1802; more than 75 years before Edison.  His “arc light” was unsuitable for mainstream application though it found specialty uses even today. Many more designs for incandescent light and lightbulbs were developed by several inventors, but neither were they practical nor suitable beyond demonstration stage. Prominently, Joseph W. Swan built a working prototype of a “light bulb” in 1850 – well before Edison.

Entrepreneurial Competition

Edison had access to improved technology such as a better vacuum pump for his breakthrough design. This technology was not available to previous inventors.  Edison also developed an efficient and economical way to distribute electricity when earlier designs drained batteries quickly.  (A nice example, by the way, on how a product can go a long way when bundled with a complementing service.)

On the flip-side, Edison knew of his limitation too.  He made carbonized Japanese bamboo glow as filament between two electrodes knowing that carbonized Tungsten was the superior material.  However, the technology was not available at the time to produce a thin Tungsten thread.  We had to wait for William D. Coolidge to produce the Tungsten filament for General Electric in 1910, which is still the preferred material to illuminate our modern incandescent lightbulbs today.

This situation is typical and comparable to many big ideas that entrepreneurs work on today.  There is much competition among entrepreneurs, so every good idea usually has a handful of teams working on it independently and head-to-head at the same time.  Thus, it is highly likely that, if not Edison, another inventor would have come up with the lightbulb design we are so familiar with today.

R&D as a Legacy

Perhaps, the even more impactful and lasting heritage of Thomas Edison are not his inventions, useful as they are.  His products such as the lightbulb, phonograph, quadruplex telegraph, mimeograph, etc., have been replaced over time by more advanced technology.

Nonetheless, Edison has changed the way we discover concertedly today. Until his time, inventors matched the stereotypical image of a lonely genius experimenting and inventing in their lair burning the midnight oil over some ambitious idea.  Edison established the first research and development (R&D) organization in his famous Menlo Park lab, where a large number of researchers worked together in an orchestrated way to find solutions to specific problems coordinated strategically and systematically concerted.  Edison has industrialized research!

Until today every research-driven company or organization worldwide follows in Edison’s footsteps!  What an impressive legacy!

Summary

Disruptive innovations tend to have their origin in incremental steps and competition among inventors. First working individually and now increasingly in teams or even distributed R&D organizations across country borders.
A key success factor here is building trust and incentives within the team in order for all individual contributors to share information and findings freely.

The broader, cross-functional approach to research helps to identify ideas and technologies from other disciplines that can serve as stepping stones.  Edison used a better vacuum pump, which made his design possible.  Later, the capability to manufacture a thin Tungsten wire allowed General Electric to take the lightbulb the next level.
As the saying goes, “innovation happens at the intersections of disciplines.”  The development of the lightbulb serves as a nice example proving it to hold true once again.  Thus, innovation benefits by drawing from advances in other disciplines.

So, is disruptive innovation a myth?

Back to our original question, the story of the lightbulb is a great example for a breakthrough innovation with vast ramifications that disrupted and shaped the we live and work around the globe.

It can, however, not be seen as just one big and isolated scientific step but rather a series of many little steps in combination insights from other disciplines including manufacturing, economics and marketing leading to broad adoption that changed the world.

Lightbulb evolution (source: www.thewirelessbanana.com)
Lightbulb evolution
(source: http://www.thewirelessbanana.com)

Only when it all comes together you have a disruptive innovation like Edison’s famous design.  And it was still not the end.  The journey continued to evolve with a Tungsten wire and later fluorescence, halogen and LED lights.

In this light, every disruption seems as yet another incremental step, doesn’t it?

Join me at the Intrapreneurship Conference 2014 in The Netherlands, Dec.10-12, 2014

Meet me at the Intrapreneurship Conference 2014 at the “Kennispoort”-building of the Eindhoven University of Technology, John F. Kennedylaan 2, 5612 AB Eindhoven, The Netherlands, from December 10-12, 2014!  Contact me you are interested to attend, as I may be able to get you a discounted ticket!

Don’t miss

Why attend?

Intrapreneurship is the most powerful engine for growth. With innovation being priority #1, how are you implementing and leveraging innovation from within?

Now being organized for the fourth time, the Intrapreneurship Conference 2014 is the premier global event for Corporate Innovation Managers, Intrapreneurs, Business Managers, HR-Managers and Innovation Consultants. This is not just another conference on innovation, where you will be listening to motivational speakers all day. We intentionally keep the number of available seats at a level that enables you to really connect with everyone.
Discuss the best and next practices in implementing and leveraging intrapreneurship.  We have carefully curated a program for you that includes all relevant topics in the field of intrapreneurship, and invited experienced intrapreneurs and experts to co-create an impactful learning experience for you.

You will leave the conference with a clear action plan and practical tools for the next step in implementing intrapreneurship.  Plus, you will meet like-minded people to connect, share and collaborate with – as most Intrapreneurs are the lone mavericks in the corporate jungle.

Meet me at AlphaSights’ Knowledge Summit in NYC, Nov. 19, 2014

Event

The AlphaSights Knowledge Summit – Accessing Critical Business Knowledge Safely and Securely in the 21st Century
at the Harvard Club of New York City, 27 W 44th St, New York, NY 10036

Overview

In today’s digitally connected economy, competitive advantage no longer comes from ‘hard’ assets. It’s human assets – knowledge and talent – that give companies and investors an edge.

Specialist knowledge can be accessed, shared and recombined quicker than ever before, driving innovation, interactivity and wealth creation. But knowledge lies at the heart of the next billion-dollar company as much as it lies at the heart of billion-dollar trade-secret lawsuits or insider trading convictions. Leading professionals and their employers find themselves in the crosshairs of litigious competitors and ambitious prosecutors more often than ever before.
At this Knowledge Summit, acclaimed thought-leaders, top lawyers, former federal prosecutors and leading practitioners will explore and discuss current best-practice in the acquisition and protection of knowledge in today’s globally connected economy.

Why attend? – Other than just meeting me 🙂

Every organization needs to access external knowledge to succeed. But what type of knowledge delivers a competitive edge, and how can it be accessed both safely and efficiently?

Network with and learn from fellow senior legal, compliance and commercial executives from the world’s leading investment and advisory firms at the Harvard Club in New York City. Over a half-day event, the Summit will discuss:

  • Best-practice policies and procedures for effective knowledge acquisition. What systems and practices do the top investment funds and leading lawyers recommend?
  • Where can public and private investors trip up when seeking alpha? Lessons from Operation Perfect Hedge and recent private equity litigation.
  • Why the exchange of knowledge has always driven human progress, and what the ramifications of a totally interconnected global marketplace might be.
  • Redrawing the battle lines for talent and knowledge as employees move ever more freely between firms – should smart employers embrace or be wary of the ‘free-agent’ economy?

 

Meet me at Yale’s “Patients and Big Data in Healthcare: Deriving Value and Accelerating Innovation” Nov.11, 2014

Patients and Big Data in Healthcare: Deriving Value and Accelerating Innovation
Nov 11 @ 4:00 pm – 6:00 pm

REGISTER:  https://www.eventbrite.com/e/patients-and-big-data-in-healthcare-deriving-value-and-accelerating-innovation-tickets-12475417309

CURE and Yale, in collaboration with Boehringer Ingelheim, presents “Patients and Big Data in Healthcare: Deriving Value and Accelerating Innovation.” In an increasingly digital age, healthcare stakeholders can access significant amounts of data and knowledge using various platforms. Critically, this “big data,” represents a vast quantity of complex and diverse information. While payers, providers, healthcare experts and the pharmaceutical industry have the capability to analyze this data to gain insight, this information can be overwhelming to patients. This BioHaven event, moderated by Richard Foster, has convened a panel of experts to explore the topic of “big data,” the role of the patient in data analytics, the role of payers and what actionable data represents. Further discussion will explore the state of the art, including discussing national hospital systems using big data and local ones in CT and at Yale. Finally, the discussion will conclude with discussion about effectively incorporating big data into operations and where the field is headed.

Special kudos to my valued colleague Faye Lindsay, who was instrumental in pulling this event together!

Some of the topics the moderator and panelists will consider:

Defining and Exploring the topic

  • Tell us what “big data” means to you and why it is important.  Give us one example which illustrates the best use of big data to date.
  • What is the role of the patient in data analytics?  Does it benefit them?  Do they naturally do it?  How error prone are the data they provide directly?
  • What is the role of the payer in all of this.  Can they get the data they need to better set rates?  Will “big data” help or hurt the payers?
  • What is actionable data?  What are the three major areas where we are making progress?

State of the Art

  • Where is the best state of the art in using data to improve outcomes in the US?  How do we know that is true?
  • What hospital systems or MCOs are most advanced?
  • How are we doing in CT compared to other states?  How do we know?
  • What is the state of the art in healthcare info tech/big data in the US.   Where?  Why?  What do we need to do to catch up?

Unanticipated Consequences

  • Will all this measurement result in intense, and from time time, unproductive rivalries between docs, or hospital systems?
  • How can the providers use “big data” and not put at risk the effectiveness of current medical care delivery processes which have takes years to define and perfect?

Specific Subtopics

  • Big Data and the bottom 5%
  • We know we spend $1.35 T on 5% of the population. Do we know who they are and how we can best treat them.  How much can we expect to reduce the cost, or improve the quality of the health care delivered to these patients?
  • Big Data and Quality
  • Integrating Big Data into Operations, effectively

What is coming?

  • Who is controlling the pace of advance in Big Data these days – Academia (who), the Payers (who?), the providers (who?) the Feds (who and who in HHS/CMS?)  What about the role of the National Cancer Hospitals.  Or other specialized (by disease/condition) providers (e.g. DaVita)

Moderator:

Richard N. Foster, PhD, Emeritus Director, McKinsey and Co; Lecturer, Yale School of Management.

Dr. Foster is an emeritus director of McKinsey & Company, Inc. where he was a Director and Senior Partner. While at McKinsey he founded several practices including the healthcare practice and the private equity practices, the technology practice and innovation practice. From 1995 to 1998 he led McKinsey’s worldwide knowledge development.

At Yale, Dr. Foster teaches “Managing In Times of Rapid Change” and serves as the Executive in Residence at the Yale Entrepreneurial Institute. Dr. Foster’s research interests are in the relationships between capital formation, innovation, and regulation. Dr. Foster has written two best-selling books: Innovation: The Attacker’s Advantage (1986) and Creative Destruction (2001), both of which were cited as among the “ten best books of the year” when they were published by the Harvard Business Review.

Dr. Foster’s work has appeared in Business Week, the Wall Street Journal, the New York Times as well as several dozen articles in research and popular journals. Dr. Foster was recognized as one of their ten “Masters of Innovation” in the past century. He was the external leader of the Concil on Foreign Relations Study Group on Technological Innovation and Economic Performance which led to the publication of Technological Innovation Economic Performance (2001, Princeton University Press).

Panelists:

Harlan Krumholz, MD, Harold H. Hines Jr. Professor of Medicine (Cardiology) and Professor of Investigative Medicine and of Public Health (Health Policy); Co-Director, Clinical Scholars Program; Director, Yale-New Haven Hospital Center for Outcomes Research and Evaluation.

Dr. Krumholz’s research focuses on improving patient outcomes, health system performance and population health. His work with health care companies has led to new models of transparency and data sharing. His work with the U.S. government has led to the development of a portfolio of national, publicly reported measures of hospital performance. These measures also became part of several provisions of the health reform bill. He is currently working with leaders in China on government-funded efforts to establish a national research and performance improvement network.

Dr. Krumholz is an elected member of the Institute of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation. He is a Distinguished Scientist of the American Heart Association. He serves on the Board of Trustees of the American College of Cardiology, the Board of Directors of the American Board of Internal Medicine and the Board of Governors of the Patient-Centered Outcomes Research Institute.

Rishi Bhalerao, MBA, Director of PatientsLikeMe, a free patient network and real-time health research platform.

At PatientsLikeMe Rishi manages major relationships with industry partners. Prior to joining PatientsLikeMe, Rishi spent several years as a management consultant with the Boston Consulting Group (BCG), and more recently, as an innovation consultant, at a firm started by Prof. Clay Christensen of the Harvard Business School. He earned an MBA from the Ross School of Business at the University of Michigan and also holds undergraduate and graduate degrees in Engineering.

You Xi

Director of Business Analytics at Boehringer Ingelheim Pharmaceuticals (BI)and leads a team of analysts conducting analysis across all BI’s portfolio and communicating findings and strategic insights to internal stakeholders (Marketing, Sales, Managed Markets, Sr. Management etc.).

The key deliverables include using various data sources to measure performance, build promotional mix optimization modeling, behavior segmentation, portfolio optimization, etc.  Prior to BI, You was a consultant at ZS Associates and then held various management roles in the pharmaceutical industry including Takeda Pharmaceuticals and Novartis.

Michael Matteo

Mike Matteo is chief growth officer at Optum, where he is responsible for creating and enabling growth across the company. Matteo focuses on the needs and opportunities of Optum’s customers and how the company can deliver creative, innovative solutions that meet their objectives. Prior to bringing his passion for modernizing the health care system to Optum in 2012, Matteo served for four years as chief executive officer of UnitedHealthcare National Accounts, where he expanded the company’s industry-leading position in the large-employer marketplace. Prior to becoming CEO, Matteo led business development efforts for UnitedHealthcare National Accounts, where previously he worked in product development and was instrumental in designing and launching the company’s first consumer-driven product innovations. He joined UnitedHealth Group in 1997 as a strategic account executive, helping many of the company’s largest employer clients meet their health care objectives.

Before joining UnitedHealth Group, Matteo was with Physicians Health Services, where he served the needs of major clients as an underwriting director and senior account executive. He began his career serving in multiple roles with Traveler’s Insurance Companies. Matteo graduated magna cum laude with honors from the College of the Holy Cross, and participated in the Columbia University Executive Management Program. He is on the boards of the MetroHartford Alliance, Hartford YMCA, and Connecticut Science Center, and served as chairperson of the Greater Hartford Arts Council Capital Campaign.

Don’t miss Gati Dharani on ‘Wearables for Health Intervention in Aging Population’ @APHA, Nov.17, New Orleans

It’s a billion dollar question: How can we use wearable mobile devices for better health outcomes in the aging population?  Join my valued colleague and HITLAB innovator Gati Dharani and her team revealing newest research in sights on “Wearable fitness tracker intervention increases physical activity in Baby Boomers” at the American Public Health Association’s (APHA) HEALTHOGRAPHY 142nd Annual Meeting and Exposition on November 15-19, 2014, in New Orleans, Louisiana.

Why is this a billion dollar question? – The traditional business model of the pharmaceutical industry is broken.  The focus shifts to incentivize patient-centric outcomes, prevention and behavior change in the global battle against a mounting wave of chronic diseases such as diabetes.  In search for a new business “beyond the pill” the pharmaceutical industry joins other stakeholders in the healthcare system to align and pull in this same direction.  First data-driven results are highly anticipated – well, here they are, so don’t miss this milestone event!

Meet me at “Healthcare Delivery to Developing Countries Using Mobile Technology” in NYC, Oct. 22, 2014

The German Center for Research and Innovation and Physicians Interactive offers a high-level panel discussion on “Healthcare Delivery to Developing Countries Using Mobile Technology” at the German House, 871 United Nations Plaza (First Ave. at 49th Street), New York, NY.  on Wednesday, October 22, 2014, from 6:00 p.m. – 8:00 p.m.  – Click here to sign up for an invite to this RSVP event.

Why?

The United Nations reports that a child born in the developing world is 33 times more likely to die by age five than a child born in the U.S. or in Germany. Tragically, the leading causes of death are entirely preventable. Given the shortage of health care providers worldwide and the explosive proliferation of mobile phones, devices, and apps, mobile health technology has a tremendous opportunity to help improve health in developing countries. How can we best deploy mobile health technology to help save lives and empower communities? Is there a role for human rights advocacy in the campaign to increase access to quality care? And, what lessons can the West learn from the developing world with regards to solving the problems of access, affordability, and even innovation?

Expert panelists address these and other pertinent questions about using mobile technology to solve the health care crisis:

  • Kerry Kennedy – President, Robert F. Kennedy Center for Justice and Human Rights
  • Donato J. Tramuto – CEO & Chairman, Physicians Interactive
  • Bernd Altpeter – CEO & Founder, German Institute for Telemedicine and Health Promotion (DITG)

moderated by


Speaker Biographies:

Kerry Kennedy is President of the Robert F. Kennedy Center for Justice and Human Rights. She is the bestselling author of Being Catholic Now and Speak Truth to Power. Ms. Kennedy started working in human rights in 1981 when she investigated abuses committed by U.S. immigration officials against Salvadoran refugees. Since then, her life has been devoted to the pursuit of justice and to the promotion and protection of basic rights. She established the RFK Center for Justice and Human Rights in 1988 and has led over 50 human rights delegations across the globe. Ms. Kennedy founded RFK Speak Truth to Power, a global human rights education initiative that is taught to millions of students worldwide.  In 2010, she founded RFK Compass, which convenes financial leaders to consider the impact of human rights violations, environmental degradation, and corruption on investment outcomes. Ms. Kennedy is Chair of the Amnesty International USA Leadership Council and serves on the boards of directors of Human Rights First, Inter-Press Service, and the United States Institute for Peace. She has three daughters, Cara, Mariah, and Michaela.

Donato J. Tramuto, Founder, CEO, and Chairman of Physicians Interactive, has more than 30 years of healthcare experience in both the product and service segments. Mr. Tramuto is the Chairman and Founder of the Tramuto Foundation, a non-profit organization that he created in 2001 to help young individuals achieve their educational goals and has also supported more than 40 organizations worldwide in helping the disadvantaged of our land.  In 2011, following the devastating effects from the earthquake in Haiti, Mr. Tramuto founded Health eVillages, a program now residing at the Robert F. Kennedy Center for Justice & Human Rights and funded through Physicians Interactive, which provides state-of-the-art mobile health technology to medical professionals in the most challenging clinical environments around the world. Mr. Tramuto serves on several executive leadership boards:  The Boston University School of Public Health Dean’s Advisory Board, the Physicians Interactive Board of Directors, the Robert F. Kennedy U.S. Leadership Council, the Robert F. Kennedy Center for Justice & Human Rights Europe Board, the HealthWays (NASDAQ) Board of Directors, and the Maine Economic Council. In 2005, 2009, and 2012, he was selected by PharmaVoice as one of the Top 100 Most Inspirational Healthcare Leaders in the Life Sciences Industry. Mr. Tramuto was selected as one of four distinguished recipients of the 2014 Ripple of Hope Award from the Robert F. Kennedy Center for Justice & Human Rights.

Bernd Altpeter is Founder and CEO of the German Institute for Telemedicine and Health Promotion (DITG). Prior to this, he founded the boutique consulting firm “driving growth group,” which works for German and international life science companies. Previously, Mr. Altpeter was Global Business Partner at Monitors Marketing Practice M2C. Since 2006, he has been operating as a consultant, business angel, and entrepreneur in the eHealth business. In March 2013, he founded DITG, which to date has evolved into one of the leading eHealth companies in Germany, offering lifestyle intervention programs for chronic diseases such as type 1 and type 2 diabetes, in addition to servicing international companies in various sectors from health insurance to the pharmaceutical industry. Mr. Altpeter studied economics in Germany, France, and the U.S.
Moderator Biography:

Wolfgang Renz is President of International Business at Physicians Interactive. Prior to this role, Dr. Renz was Corporate Vice President of Business Model & HealthCare Innovation at Boehringer Ingelheim, one of the world’s largest pharmaceutical companies. For over a decade, he has been involved in developing medicines and technology to help people lead healthier, more productive lives. At Boehringer Ingelheim, he led a team of specialists to find, test, and develop the disruptive technologies that will shape the way healthcare will be delivered in the future. In addition, he currently also serves as Adjunct Professor of Surgery at McGill University’s Faculty of Medicine in Montreal, Canada. Dr. Renz holds a medical degree and a Ph.D. from Freiburg University and is board certified in Germany in emergency medicine.

Meet me at DEMO Enterprise, San Francisco/CA, April 3, 2014

DEMO Enterprise, San Francisco/CA, April 3, 2014
DEMO Enterprise, San Francisco/CA, April 3, 2014

New Tech Solving Big Problems!

Mastering the connected economy – key findings of IBM’s 2012 CEO study

In IBM’s 2012 CEO Study, top leaders identified openness and collaboration as the critical areas to master change in the coming years – how do leadership and employees prepare for the new challenges?

About the CEO study

IBM conducts a ‘CEO Study’ every other year, interviewing more than 1,700 CEOs and public sector leaders from around the world on their views.  The top leaders identified openness and collaboration as the critical areas to address and master our ‘connected economy’ over the coming years.

Two years ago, the focus of the 2010 study was on managing the increasing complexity raising the question: Complexity is the 2015 challenge! – Are leaders ready for ‘glocal’?

What’s new in 2012?

This year’s CEO Study looks into the future of 2015 to 2017.  The focus shifts to leveraging the softer factors, namely people and innovation, to navigate and connect in an increasingly technology-driven world that reshapes the workplace and the marketplace.  The CEOs agree that change is the only constant.  There is no ‘normal’ anymore – say good-bye to a stable status quo and expect unpredictability!

Let’s look at some key findings:

IBM 2012 CEO Study

Pivotal technology

Technology is the enabler for relationships and collaboration in the new age.  What has changed is how people interact with others as well as with and within organizations.  Technology now ranks number one of all external factors that influence organizations – surpassing people skills and market factors, which reflects a dramatic shift over the past years.  This makes technology the driver and single most important differentiator for successful organizations as 75% of CEOs agree – and a field that organizations cannot afford to fall behind in.

Outperforming organizations prepare for the convergence we see in the “digital, social and mobile spheres – connecting customers, employees, and partners in new ways to organizations and to each other.”  Thus, the driving forces for success in organizations remain with innovation and people to master and leverage technology.

Future leadership traits

What does this mean for leaders?  What are the traits looked for in leaders to master the challenge?

Organizations look for leaders that inspire.  Leaders who are obsessed with understanding their customer as a persona and what drives their individual behavior.  Leaders who work as a team across the C-level suite to align and combine the organization’s assets and strengths.

Half of the CEOs expect social channels to be a primary way to engage customers.  No wonder that outperforming organizations are those who have the ability to translate data effectively into insights and insights into action, or so 84% of the study responders believe.

These organizations manage change better.  They are open to venture into other industries or explore even more disruptive innovation by creating entirely new industries and business models.  Strong analytical capabilities to uncover patterns are only one side of the coin, where the other is creative and connected minds that can answer questions no one thought to ask in the first place.

Innovation dilemma

But what if your organization is not the out-performer?  What does it take your organization to get there?

It is no secret that large companies tend to lose their innovative momentum; see Starting an ERG as a strategic innovation engine!  (part 3 of 3).  To compensate the lack of creativity within, they buy start-ups, for example, or focus on hiring only the best and brightest (a.k.a. ‘war on talent’) to fuel their future idea and product pipelines.

What happens in reality, however, is that hiring managers like to look at the ‘odd-ball’ applicant, the out-of-the-box thinker they acclaim to look for, but then play it safe when it comes to decision time and go with a ‘lower risk’ candidate instead.

This leads to the next dilemma: Job applicants noticed the trend and adapted.  There is new truth to the survival of the fittest:  When you look at applicants for management positions, you may notice that their resumes and interview responses became increasingly similar over the past years.  They present themselves homogenous and ‘smooth’ with as little personal ‘edges’ as possible that may stick out and cause controversy.  The common theme you hear is the mistakes the candidates would not make – rather than articulating what they would do in their new role.

Risk-avoidance wins over leadership taking charge.  This mindset works its way down the hierarchy and across the organization.  You can notice it in narrow job descriptions, many detailed rules, and processes full of ‘red tape’.  It does not surprise that innovation perishes in large organizations and management turns to buy fresh ideas from the outside in one way or another.

Innovation from within

Innovation means taking risks; yet we tend to hire ‘safe’ and complacent managers and leaders that don’t rock the boat too much.  What we get in the end is a somewhat harmonized workforce that lacks diversity of thought ‑ despite possibly matching more visible and publicly promotable diversity criteria (see also How to create innovation culture with diversity!).

Reinventing innovation from within an organization is not always easy.  It requires top management commitment to build a strong internal framework and foster intrapreneurship throughout the workforce.  It takes establishing a reliable, predictable, and continuous innovation process with room to experiment and learning from failure.  For a simple reason, all this is necessary to succeed: you cannot leave your workforce behind if you seek creative ideas that lead to the next discovery and breakthrough.  – Read more on How to become the strategic innovation leader?  (part 2 of 3).

Employees of the Future

Ever-new technological advances shifted change to the unpredictable: pervasive smart-devices, mobility, virtual social networks and the ‘big data’ flood this combination generates, new business models they enable, and so on.  Organizations cannot even anticipate anymore what skills their workforce will need in only three or so years from now.

Consequently, rather than looking for specific skills (which is the starting point for the “war on talent”) they look for flexibility in employees to create and respond to disruptive innovations and change to new businesses and business models.  The most valued future employees must be comfortable with change and ambiguity, able to adapt and even reinvent themselves while leveraging their personal networks for professional success.  This is why human capital is seen most important (by 71% of CEOs) to make connections that fuel creativity and innovation for sustained economic value and growth.

The 2012 ‘Pulse of the Profession’ study by Project Management Institute (PMI) comes to similar results from a project management perspective: It notes that organizations seek to become more agile by placing more importance on change management and project risk management as well as on talent management to grow and conquer new markets.

Lead with openness and values

It requires more than inspiration to tap into employees effectively and on a deeper level than what their job description outlines.  Setting tight rules proves counterproductive, since the surrounding ambiguity makes it impossible to foresee and regulate all possible cases.

Quite the opposite is needed:  opening up and establishing a framework of values that guide employees in their response and dealing with unforeseen situations and customer interactions.  This value framework provides a bed for ideas to flow freely but also to connect with employees and let them to bring their whole self to work ‑ including their social networks.

Yet, in an increasingly connected world, innovation cannot come from inside of the organization alone.  Out-performers take risks by accepting and inviting innovative sparks from outside their own organization in ‘win-win’ partnerships that amplify innovation for growth.  Within, they communicate a clear purpose and mission with ethics and values that resonate with and guide their staff while fostering a collaborative environment.

Innovation Partnerships and Alliances

Many have tried to make it to the top alone but only few organizations truly understood how to integrate and control their entire value chain in sustainable ways.  As a lesson to learn from, Apple stands as an example for a company that was close to losing everything but learned from its mistakes.  Apple famously re-invented itself to become to most validated company worldwide (read more how Apples did it in Innovate to Implement!)

Success requires a broad organizational open-mindedness and flexibility to think and act disruptive were needed.  The CEOs see the future in innovation partnerships and close alliances where organizations share their data and collaborate on a deeper level than before without holding tight control.

– Are you ready to taking the leap to open up?

%d bloggers like this: